Farmaindustria trusts that Spain's new national strategic plan regarding hepatitis C will provide a rational access to new medicines

Faced with the problem that has arisen in the last few months with regards to the access to new treatments for hepatitis C, as well as with the information and opinions expressed, sometimes contradictory, on these new medicines, Spanish pharma trade group Farmaindustria says it would like to thoroughly support the government and offer its collaboration with the aim of making an accurate diagnosis of the number of patients who need to be treated.

Farmaindustria would also like to elaborate a protocol of action so that health care professionals, based on clinical criteria, are able to define the most appropriate health care interventions with these new therapies.

Likewise, it publicly recognizes the efforts made by health care authorities to include these medicines against hepatitis C through the public reimbursement system (three have already been approved and two more will soon be), making Spain one of the countries in Europe where these treatments have been approved earlier on in favorable economic conditions.